02.10.2015 Views

studies

2015SupplementFULLTEXT

2015SupplementFULLTEXT

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 493A<br />

outcomes in a multi-center cirrhotic cohort. Methods: NACSELD<br />

(North American Consortium for End-Stage Liver Disease)<br />

enrolls hospitalized cirrhotics from 16 centers. Data collected<br />

are admission/cirrhosis details, inpatient details & 30-day mortality.<br />

Details & outcomes of pts given (Alb) /not given albumin<br />

(no Alb) and regional variations were compared. Within<br />

Alb, evidence-based indications (AKI, SBP, paracentesis) were<br />

compared to others. Results: 988 cirrhotics (64% men, MELD<br />

19, 43%alcohol) were included. 597(60%) pts received a<br />

280±267 gm of albumin. Alb pts had worse cirrhosis severity<br />

but similar demographics as non-alb(Table).Albumin use: The<br />

majority(76%) was evidence-based (47%AKI, 34%paracentesis<br />

& 14%SBP). Remaining 24% was for hyponatremia (12%),<br />

non-SBP infection (6%) & anasarca (6%). This resulted in AKI<br />

resolution in 28%, reduced anasarca in 22%, improved Na in<br />

12% & allowed paracentesis in 30% of pts. 4% had adverse<br />

events (3% fluid overload & 1% pulmonary edema) Regional<br />

variation: 4 regions: 3 US (1: North, 2: South, 3: Southwest)<br />

& Canada (region 4) were studied. Region 3 had the highest<br />

albumin use (69%) with lowest evidence-based use (57%) compared<br />

to Region 2 that used the least(45%,p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!